Literature DB >> 8844426

Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography.

S M Mansor1, V Navaratnam, N Yahaya, N K Nair, W H Wernsdorfer, P H Degen.   

Abstract

A rapid and selective high-performance liquid chromatographic assay for determination of a new antimalarial drug (benflumetol, BFL) is described. After extraction with hexane-diethyl ether (70:30, v/v) from plasma, BFL was analysed using a C18 Partisil 10 ODS-3 reversed-phase stainless steel column and a mobile phase of acetonitrile-0.1 M ammonium acetate (90:10, v/v) adjusted to pH 4.9 with ultraviolet detection at 335 nm. The mean recovery of BFL over a concentration range of 50-400 ng/ml was 96.8 +/- 5.2%. The within-day and day-to-day coefficients of variation were 1.8-4.0 and 1.8-4.2%, respectively. The minimum detectable concentration in plasma for BFL was 5 ng/ml with a C.V. of less than 10%. This method was found to be suitable for clinical pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844426     DOI: 10.1016/0378-4347(96)00086-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  8 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.

Authors:  Rina P M Wong; Sam Salman; Kenneth F Ilett; Peter M Siba; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

3.  Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.

Authors:  Peter Starzengruber; Gunther Wernsdorfer; Maria Parizek; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study.

Authors:  Liusheng Huang; Patricia S Lizak; Anura L Jayewardene; Florence Marzan; Ming-Na Tina Lee; Francesca T Aweeka
Journal:  Anal Chem Insights       Date:  2010-03-29

5.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.

Authors:  Gilbert Lefèvre; Polly Carpenter; Claire Souppart; Heinz Schmidli; Mark McClean; Daria Stypinski
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

6.  Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.

Authors:  Francesco Checchi; Patrice Piola; Carole Fogg; Francis Bajunirwe; Samuel Biraro; Francesco Grandesso; Eugene Ruzagira; Joseph Babigumira; Isaac Kigozi; James Kiguli; Juliet Kyomuhendo; Laurent Ferradini; Walter R J Taylor; Jean-Paul Guthmann
Journal:  Malar J       Date:  2006-07-19       Impact factor: 2.979

7.  A simple and precise method for quantitative analysis of lumefantrine by planar chromatography.

Authors:  Purnima Hamrapurkar; Mitesh Phale; Sandeep Pawar; Priti Patil; Mittal Gandhi
Journal:  Pharm Methods       Date:  2010-10

Review 8.  Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.

Authors: 
Journal:  BMC Med       Date:  2015-09-18       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.